NCT02143960已完成不适用
Clinical Study to Evaluate the Performance of the VelaShape III Device in Comparison to Cryolipolysis for Reduction in Waist / Love Handles / Flanks.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- A blinded rating of the treatment area
研究概览
简要总结
The purpose of this study is to compare the clinical performance of the VelaShape III device with CoolSculpt for reduction of the waist, love handles and flanks.
详细描述
VelaShape is a non-invasive (not breaking the skin) device for Body Reshaping and Cellulite Treatment. VelaShape combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation.
The CoolSculpt System is a noninvasive device that reduces fat by freezing fat cells until they break apart.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Informed consent process completed and subject completed consent.
- •Fitzpatrick Skin Type I to VI
- •Having excess fat deposits bilaterally in the waist / love-handle / flank areas.
- •BMI score is greater than 18.5 and less than 29.9 - normal to overweight, but not obese.
- •Willing to follow the treatment and follow-up schedule and post-treatment care instructions.
- •Willingness to refrain from a change in diet/ exercise/medication regimen for the entire course of the study.
- •If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
- •Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.
排除标准
- •Subjects with history of excessive weight fluctuation or expect to gain/lose more than 5 pounds) during the study time frame.
- •Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
- •Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
- •Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone.
- •Known photosensitivity.
- •Having received treatment with laser, RF or other devices in the treated areas within 6 months of treatment or during the study.
- •Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction.
- •Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
- •Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders.
- •Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
- •History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
- •Suffering from hormonal imbalance which may affect weight as per the Investigator's discretion.
- •History of significant lymphatic drainage problems or impaired circulation in the area to be treated.
- •Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
- •History of keloid scarring, abnormal wound healing and / or prone to bruising.
- •History of epidermal or dermal disorders (particularly if involving collagen or microvascularity).
- •Use of isotretinoin (Accutane®) within 6 months of treatment or during the study.
- •Allergy to any component of the lotion (VelaSpray Ease) used in this study.
- •Cryoglobulinemia, Paroxysmal cold hemoglobinuria, or any known sensitivity to cold such as cold urticaria or Raynaud's disease.
- •Neuropathic disorders such as post-herpetic neuralgia or diabetic neuropathy, or impaired skin sensation in the area to be treated.
- •Hernia in the area to be treated.
- •Participation in a study of another device or drug within 9 month prior to enrollment or during this study, if the treated area was involved.
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
结局指标
主要结局
A blinded rating of the treatment area
时间窗: 3 month post treatment
Improvement scores of photographs for the treatment side with the VelaShape III device versus the side treated with CoolSculpt will be blindly evaluated by independent reviewer at baseline and at 3 month post treatment time-point.
次要结局
- A blinded rating of the treatment area(1 week, 1 month and 6 months post treatment)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
VelaShape and Contour I V3 for Abdominal Fat Reduction vs. ControlUnwanted Abdomen FatNCT02553278Syneron Medical24
已完成
不适用
VelaShape III & UltraShape Power for Thigh Circumference ReductionCircumference ReductionNCT03430245Syneron Medical16
已完成
不适用
Ultrashape System in Combination With VelaShape II Device for Circumferential ReductionAbdominal FatNCT02154113Syneron Medical21
进行中（未招募）
3 期
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal InsulinDiabetesNCT06767748Gan & Lee Pharmaceuticals.620
进行中（未招募）
3 期
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)DiabetesNCT06767735Gan & Lee Pharmaceuticals.580